Critical Contrast: Stevanato Group (NYSE:STVN) & Rapid Micro Biosystems (NASDAQ:RPID)

Rapid Micro Biosystems (NASDAQ:RPID) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Rapid Micro Biosystems and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Stevanato Group	10.99%	10.43%	6.16%

Analyst Ratings

This is a summary of current recommendations and price targets for Rapid Micro Biosystems and Stevanato Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	2	1	2.75
Stevanato Group	0	4	2	2	2.75

Rapid Micro Biosystems presently has a consensus target price of $5.00, suggesting a potential upside of 518.81%. Given Rapid Micro Biosystems’ higher probable upside, analysts plainly believe Rapid Micro Biosystems is more favorable than Stevanato Group.

Earnings and Valuation

This table compares Rapid Micro Biosystems and Stevanato Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59 million	1.21	-$47.12 million	($1.12)	-0.72
Stevanato Group	$1.34 billion	4.31	$158.21 million	€0.56	34.10

Stevanato Group has higher revenue and earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rapid Micro Biosystems has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Summary

Stevanato Group beats Rapid Micro Biosystems on 9 of the 13 factors compared between the two stocks.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.